TABLE 1.
Dataset characteristics
| Aβ− control | Preclinical AD (Aβ+ control) | Early prodromal AD (Aβ+ EMCI) | |||
|---|---|---|---|---|---|
| CSF p‐tau negative (T−) | CSF p‐tau positive (T+) | Whole group | |||
| Number of subjects | 151 | 32 | 36 | 76 | 110 |
| Age (years) | 71.5 (6.2) | 74.3 (5.9)* | 74.7 (5.5)** | 74.4 (5.8)*** | 72.8 (6.9) |
| Sex (male/female) | 83/68 | 12/20 | 10/26** | 25/51** | 63/47 |
| Education (years) | 16.9 (2.3) | 16.5 (2.6) | 15.9 (2.9)* | 16.1 (2.8)* | 15.7 (2.8)*** |
| MMSE | 29.1 (1.2) | 28.9 (1.0) | 29.2 (0.9) | 29.1 (0.9) | 28.0 (1.7)*** |
| Mean number of timepoints | 4.3 (1.0) | 4.1 (1.2) | 3.9 (1.3) | 4.0 (1.2) | 4.8 (0.5)** |
Notes: All statistics are in comparison to Aβ− control. SD is reported in parenthesis. Independent two‐sample t‐test (continuous variables with normal distribution, including age, education, and mean number of timepoints), Mann–Whitney U test (continuous variable with nonnormal distribution, i.e., MMSE) and contingency χ2 test (sex) were performed.
Abbreviations: AD, Alzheimer's disease; Aβ, amyloid‐β; CSF, cerebrospinal fluid; EMCI, early mild cognitive impairment; MMSE, mini‐mental state examination.
*p < 0.05; **p < 0.01; ***p < 0.001.